<!doctype html><html lang=fr><head><meta charset=UTF-8><meta name=viewport content="width=device-width,initial-scale=1"><title>Note d‚ÄôAllurion Technologies relev√©e suite √† l‚Äôapprobation de la FDA - Investing.com France | Mounjaro News</title><meta name=description content="Le Mounjaro franchit une nouvelle √©tape importante dans sa reconnaissance mondiale."><meta name=author content="Mounjaro News"><meta name=keywords content="Mounjaro,tirz√©patide,tirzepatide,GLP-1,Note d‚ÄôAllurion Technologies relev√©e suite √† l‚Äôapprobation de la FDA - Investing.com France"><meta name=robots content="index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1"><meta name=language content="fr"><meta name=revisit-after content="1 day"><link rel=canonical href=https://mounjaronews.info/posts/2026-03-01-note-d-allurion-technologies-relevee-suite-a-l-approbation-d/><link rel=alternate hreflang=fr href=https://mounjaronews.info/posts/2026-03-01-note-d-allurion-technologies-relevee-suite-a-l-approbation-d/><link rel=alternate hreflang=en href=https://mounjaronews.info/posts/2026-03-01-note-d-allurion-technologies-relevee-suite-a-l-approbation-d/><link rel=alternate hreflang=x-default href=https://mounjaronews.info/><meta property="og:site_name" content="Mounjaro News"><meta property="og:title" content="Note d‚ÄôAllurion Technologies relev√©e suite √† l‚Äôapprobation de la FDA - Investing.com France | Mounjaro News"><meta property="og:description" content="Le Mounjaro franchit une nouvelle √©tape importante dans sa reconnaissance mondiale."><meta property="og:url" content="https://mounjaronews.info/posts/2026-03-01-note-d-allurion-technologies-relevee-suite-a-l-approbation-d/"><meta property="og:locale" content="fr_FR"><meta property="og:locale:alternate" content="en_US"><meta property="og:type" content="article"><meta property="article:published_time" content="2026-03-01T07:54:10+01:00"><meta property="article:modified_time" content="2026-03-01T07:54:10+01:00"><meta property="article:author" content="Mounjaro News"><meta property="article:section" content="Sant√© / Health"><meta property="article:tag" content="Mounjaro"><meta property="article:tag" content="Tirz√©patide"><meta property="article:tag" content="GLP-1"><meta property="article:tag" content="Diab√®te"><meta property="article:tag" content="Perte de poids"><meta name=twitter:card content="summary_large_image"><meta name=twitter:title content="Note d‚ÄôAllurion Technologies relev√©e suite √† l‚Äôapprobation de la FDA - Investing.com France | Mounjaro News"><meta name=twitter:description content="Le Mounjaro franchit une nouvelle √©tape importante dans sa reconnaissance mondiale."><script type=application/ld+json>{"@context":"https://schema.org","@type":"WebSite","name":"Mounjaro News","url":"https:\/\/mounjaronews.info\/","description":"Toute l\u0027actualit√© du Mounjaro (tirz√©patide) ‚Äî articles reformul√©s et traduits chaque jour par IA","inLanguage":["fr-FR","en-US"],"about":{"@type":"Drug","name":"Tirzepatide","alternateName":["Mounjaro","Zepbound"],"sameAs":"https://www.wikidata.org/wiki/Q113523571"}}</script><script type=application/ld+json>{"@context":"https://schema.org","@type":"NewsArticle","headline":"\"Note d‚ÄôAllurion Technologies relev√©e suite √† l‚Äôapprobation de la FDA - Investing.com France\"","description":"\"Le Mounjaro franchit une nouvelle √©tape importante dans sa reconnaissance mondiale.\"","datePublished":"2026-03-01T07:54:10\u002b01:00","dateModified":"2026-03-01T07:54:10\u002b01:00","inLanguage":["fr-FR","en-US"],"author":{"@type":"Organization","name":"Mounjaro News","url":"https:\/\/mounjaronews.info\/"},"publisher":{"@type":"Organization","name":"Mounjaro News","url":"https:\/\/mounjaronews.info\/"},"mainEntityOfPage":{"@type":"MedicalWebPage","@id":"https:\/\/mounjaronews.info\/posts\/2026-03-01-note-d-allurion-technologies-relevee-suite-a-l-approbation-d\/","medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"}},"about":{"@type":"Drug","name":"Tirzepatide","alternateName":"Mounjaro"},"isBasedOn":{"@type":"NewsArticle","url":"\"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNRlNEVmgwSWVhTzQza3NWbFRwYUIybmdHcUVfX3MzSGhESENXbzhVWEpnOW9FendZWUdWS2xTcWxfS3NIRWNKREhBRmNrT0JOUWg1MGVTREhLSHQwVFYwdDVPUG9qUVVmUFJ5ZmczSWhUYV9rb1hfWV85bmd3RUcyYkpsNXc5bkd3dVZJN21XaENocGJJTGpaWjVwYXRxdWNPRWJwYzBSUkhGd0ZDRG51Y2FxQW8xVE42N2Y1dktZYmxHZS1Rbk1RUmhUNEE3ZFVBMUVj?oc=5\""}}</script><script type=application/ld+json>{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mounjaronews.info\/"},{"@type":"ListItem","position":2,"name":"\"Note d‚ÄôAllurion Technologies relev√©e suite √† l‚Äôapprobation de la FDA - Investing.com France\"","item":"https:\/\/mounjaronews.info\/posts\/2026-03-01-note-d-allurion-technologies-relevee-suite-a-l-approbation-d\/"}]}</script><link rel=preconnect href=https://fonts.googleapis.com><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800;900&display=swap" rel=stylesheet><link rel=stylesheet href=/css/style.css><script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-4796217302525352" crossorigin=anonymous></script><script async src=https://subscribe-forms.beehiiv.com/embed.js></script><link rel=icon type=image/svg+xml href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><rect width='100' height='100' rx='20' fill='%232563eb'/><text y='68' x='50' text-anchor='middle' font-size='38' font-family='system-ui' font-weight='800' fill='white'>MNJ</text></svg>"></head><body><header class=site-header><nav class=site-nav><a href=/ class=site-logo><div class=logo-icon>MNJ</div><div class=logo-text><span class=logo-name>Mounjaro News</span>
<span class=logo-sub>Actualit√©s tirz√©patide ¬∑ FR & EN</span></div></a><ul class=nav-links><li><a href=/>Accueil</a></li><li><a href=https://www.mounjaro.com target=_blank rel=noopener>Mounjaro.com</a></li><li><a href=/#newsletter class=nav-pill>Newsletter gratuite</a></li></ul></nav></header><div class=article-header><div class=article-header-inner><a href=/ class=back-link>‚Üê Retour ¬∑ Back</a><div class=article-label>üíä Mounjaro ¬∑ Tirz√©patide</div><h1>Note d‚ÄôAllurion Technologies relev√©e suite √† l‚Äôapprobation de la FDA - Investing.com France</h1><div class=article-meta><span class=meta-chip>üìÖ 1 March 2026</span>
<span class=meta-chip>üì∞ news.google.com</span>
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNRlNEVmgwSWVhTzQza3NWbFRwYUIybmdHcUVfX3MzSGhESENXbzhVWEpnOW9FendZWUdWS2xTcWxfS3NIRWNKREhBRmNrT0JOUWg1MGVTREhLSHQwVFYwdDVPUG9qUVVmUFJ5ZmczSWhUYV9rb1hfWV85bmd3RUcyYkpsNXc5bkd3dVZJN21XaENocGJJTGpaWjVwYXRxdWNPRWJwYzBSUkhGd0ZDRG51Y2FxQW8xVE42N2Y1dktZYmxHZS1Rbk1RUmhUNEE3ZFVBMUVj?oc=5" target=_blank rel="noopener noreferrer" class=source-link>üîó Source originale</a></div></div></div><div class=article-body><div class=ad-wrapper><p class=ad-label>Publicit√©</p><ins class=adsbygoogle style=display:block;text-align:center data-ad-layout=in-article data-ad-format=fluid data-ad-client=ca-pub-4796217302525352 data-ad-slot=auto></ins><script>(adsbygoogle=window.adsbygoogle||[]).push({})</script></div><div class=lang-switcher id=langSwitcher><button class="lang-btn active" data-lang=fr onclick='switchLang("fr")'>
üá´üá∑ Fran√ßais
</button>
<button class=lang-btn data-lang=en onclick='switchLang("en")'>
üá¨üáß English</button></div><div class=bilingual-grid><div class=lang-block id=block-fr><div class=lang-header><span class=lang-flag>üá´üá∑</span> Version fran√ßaise</div><div class=lang-content><p>Le Mounjaro franchit une nouvelle √©tape importante dans sa reconnaissance mondiale. Allurion Technologies, entreprise sp√©cialis√©e dans les solutions de gestion du poids, a vu sa note relev√©e suite √† l&rsquo;approbation par la FDA am√©ricaine du tirz√©patide, principe actif du Mounjaro. Cette d√©cision r√©glementaire renforce la position du m√©dicament sur le march√© nord-am√©ricain.</p><p>Le tirz√©patide appartient √† la classe √©mergente des agonistes GLP-1, des mol√©cules qui agissent sur l&rsquo;app√©tit et la r√©gulation du glucose sanguin. Contrairement √† ses pr√©d√©cesseurs, ce compos√© cible deux r√©cepteurs distincts, ce qui explique son efficacit√© renforc√©e. Les donn√©es cliniques montrent une r√©duction significative du poids chez les patients trait√©s.</p><p>Cette approbation repr√©sente un tournant pour l&rsquo;industrie pharmaceutique et les professionnels de sant√©. Elle √©largit les options th√©rapeutiques disponibles pour les patients en surpoids ou ob√®ses, particuli√®rement ceux atteints de diab√®te de type 2. L&rsquo;int√©r√™t des investisseurs pour Allurion Technologies refl√®te la confiance accrue envers les solutions innovantes de cette cat√©gorie.</p><p>Le march√© des GLP-1 conna√Æt une expansion rapide, port√©e par la demande croissante et les avanc√©es scientifiques. Cette approbation marque une √©tape dans la d√©mocratisation des traitements anti-ob√©sit√©.</p></div></div><div class=lang-block id=block-en><div class=lang-header><span class=lang-flag>üá¨üáß</span> English version</div><div class=lang-content><p>Mounjaro reaches a critical milestone in global healthcare recognition. Allurion Technologies received an upgraded analyst rating following FDA approval of tirzepatide, the active ingredient in Mounjaro. This regulatory decision strengthens the medication&rsquo;s competitive position in the North American market.</p><p>Tirzepatide belongs to an emerging drug class known as GLP-1 agonists, molecules that regulate appetite and blood sugar levels. Unlike earlier medications, this compound targets two distinct biological receptors, which enhances its therapeutic effectiveness. Clinical trials demonstrate substantial weight reduction among treated patients.</p><p>This FDA authorization represents a turning point for pharmaceutical innovation and clinical practice. It expands treatment options for overweight and obese patients, particularly those managing type 2 diabetes. Investor enthusiasm surrounding Allurion Technologies reflects growing confidence in this category of therapeutic solutions.</p><p>The GLP-1 medication market is experiencing rapid growth, driven by increasing patient demand and scientific breakthroughs. This approval signifies a significant step toward making anti-obesity treatments more widely available and accessible.</p><p>Healthcare professionals and patients now have additional choices for managing weight-related health challenges using evidence-based pharmaceutical interventions.</p></div></div></div><div class=ad-wrapper><p class=ad-label>Publicit√©</p><ins class=adsbygoogle style=display:block;text-align:center data-ad-layout=in-article data-ad-format=fluid data-ad-client=ca-pub-4796217302525352 data-ad-slot=auto></ins><script>(adsbygoogle=window.adsbygoogle||[]).push({})</script></div><div class=newsletter-section><div class=newsletter-inner><div class=newsletter-icon>üì¨</div><h3>Recevez l'actu Mounjaro chaque matin</h3><p>Abonnez-vous gratuitement ‚Äî r√©sum√© quotidien FR & EN dans votre bo√Æte mail.
<em>Subscribe free ‚Äî daily FR & EN digest in your inbox.</em></p><iframe src=https://subscribe-forms.beehiiv.com/91587c2f-9b1e-45e3-95cf-1f8ca0fe3c4b class=beehiiv-embed data-test-id=beehiiv-embed frameborder=0 scrolling=no></iframe></div></div></div><script>function switchLang(e){const t=window.innerWidth<=700;if(!t)return;document.querySelectorAll(".lang-btn").forEach(t=>{t.classList.toggle("active",t.dataset.lang===e)}),document.getElementById("block-fr").style.display=e==="fr"?"":"none",document.getElementById("block-en").style.display=e==="en"?"":"none"}window.innerWidth<=700&&(document.getElementById("block-en").style.display="none"),window.addEventListener("resize",function(){window.innerWidth>700&&(document.getElementById("block-fr").style.display="",document.getElementById("block-en").style.display="")})</script><footer class=site-footer><div class=footer-inner><div class=footer-grid><div class=footer-brand><a href=/ class=site-logo><div class=logo-icon>MNJ</div><div class=logo-text><span class=logo-name style=color:rgba(255,255,255,.9)>Mounjaro News</span>
<span class=logo-sub>Actualit√©s tirz√©patide ¬∑ FR & EN</span></div></a><p style=margin-top:14px>R√©sum√©s quotidiens des actualit√©s sur le Mounjaro (tirz√©patide), reformul√©s et traduits par intelligence artificielle. Pas de conseil m√©dical.</p></div><div class=footer-col><h4>Navigation</h4><ul><li><a href=/>Accueil</a></li><li><a href=/#newsletter>Newsletter</a></li><li><a href=https://mounjaronews.info/sitemap.xml target=_blank>Sitemap</a></li></ul></div><div class=footer-col><h4>Ressources</h4><ul><li><a href=https://www.mounjaro.com target=_blank rel=noopener>Mounjaro.com</a></li><li><a href="https://pubmed.ncbi.nlm.nih.gov/?term=tirzepatide" target=_blank rel=noopener>PubMed</a></li><li><a href=https://www.ema.europa.eu target=_blank rel=noopener>EMA</a></li></ul></div></div><div class=footer-bottom><p class=footer-copy>&copy; 2026 Mounjaro News &nbsp;¬∑&nbsp;
Propuls√© par <a href=https://www.anthropic.com target=_blank rel=noopener style=color:rgba(255,255,255,.6)>Claude AI</a></p><p class=footer-disclaimer>‚ö†Ô∏è Site d'information uniquement ‚Äî pas de conseil m√©dical. Consultez toujours votre m√©decin.
For informational purposes only ‚Äî not medical advice.</p></div></div></footer></body></html>